insitro

Terrific listening to our CEO Daphne Koller and Jeffrey Reid of the Regeneron Genetics Center compare notes on #AI, genetics, #DEI, and talent pathways. They reinforced the urgent task of improving medicines for patients on Regeneron's new podcast, "The Nucleus." It was great to kick off the series by dissecting the underappreciated revolution in human biology “to quantitatively measure biology at high fidelity and at a high scale” and what it means for drug discovery, plus much more. Here are a few of our favorite insights from Daphne’s conversation with Jeff: 1. Why ML is essential for data-driven biology: With the explosion of tools to measure biological systems at various scales, "there's just no way for the human mind to assimilate and extract the information." But Daphne noted that “while you can interrogate biology at the level of cells, ultimately what you care about is curing humans, not cells," which is why insitro incorporates high-content human clinical data into our discovery strategy. 2. Why genetic diversity opens new windows: The more diverse the data from human genetics, the more we can explore new findings for drug discovery. Daphne shared that “variants that are only relevant in a certain subset of the population are often new windows into disease.” This is why it’s so critical “to create larger, more diverse population cohorts and make sure that they are accessible to the broader research population.” 3. Why we are using a pipeline through platform approach: insitro is building a pipeline through platform and is taking inspiration from life sciences pioneers like Regeneron. Our ML analysis models are generating and prioritizing therapeutic hypotheses, which provide the foundation for a discovery engine that will build value again and again. Daphne talked about her excitement for building a platform “that allows us to generate new therapeutic hypotheses and turn them into medicines.” A big thank you to Jeff and Regeneron for inviting us to be part of the launch of The Nucleus. We're energized by discussions like these with fellow innovators who push the boundaries of science and technology to develop transformative new treatments for patients – and look forward to tuning in to future episodes. For a deeper dive, listen to the full episode of The Nucleus here: https://lnkd.in/etun97D7

Excited to see our first intern cohort diving right in! 👏

Welcome to insitro’s new Chief Technical Operations Officer, Jennitte Stevens. Jennitte brings an impressive track record in therapeutic discovery, design and development at Amgen. Jennitte will spearhead how insitro continues to build a unique research and preclinical engine that incorporates both experimental and computational technologies to generate a pipeline of differentiated therapeutics. For close to two decades, Jennitte was closely involved in advancing a range of Amgen’s novel technologies and modalities, including biologics, synthetics, cell therapies and oligonucleotides. In total, she supported 100+ therapeutic programs, including 30+ IND submissions and 10 BLAs. She has more than 40+ publications and multiple patents to her name and was recognized for the development and use of cutting-edge technologies to improve efficiency and shorten timelines. Her expertise will play a pivotal role as our lead programs approach the clinic. With Jennitte’s laser focus on efficiency, superb leadership and a passion for patients, we couldn’t be more excited to have her on board. Join us in welcoming Jennitte in the comments below!

insitro Director, Oligonucleotide Therapeutics Arijit Bhowmick, Ph.D., discusses the rapid growth of the oligo field with David McCall and Nucleic Acid Insights. He outlines key milestones in the last decade, explains how oligos are enabling next-generation medicines and describes the advantages they offer specifically for insitro’s platform using #AI and #ML. “Our platform not only allows us to get an unprecedented insight into the transcriptomic and phenotypic effect of knocking down a target, but it also allows us to investigate off-target effects thoroughly,” notes Dr. Bhowmick. Check out the full Q&A to read more below. https://lnkd.in/e-8jtSeS

Today marks our six-year anniversary! We recently reflected on our progress and the opportunity ahead at our annual in vivo week, a signature event run by and for insitrocytes to learn, collaborate, and innovate. This year we set a new bar for inspiring scientific advances, progress in our ML models, moving keynote sessions, creative connections, and a little bit of healthy competition. There were six takeaways that stood out and propel us forward. Read more below. ⬇

We are thrilled to welcome Gwynne Oosterbaan as insitro’s new Vice President of Communications and External Affairs. Gwynne brings a wealth of experience in life sciences and corporate communications, with a focus on innovation. For the past nine years, she partnered with commercial, R&D, and technology leaders at GSK, where her scope spanned vaccines and global health, drug discovery, genomics and AI-ML, as well as culture and engagement. Her expertise, creativity and perspective couldn't come at a better time as our pipeline through platform advances towards the clinic. Her passion for public health and technology align perfectly with insitro’s mission to deliver better medicines faster, to the patients who can benefit from them most. Please join us in welcoming Gwynne to insitro!

At insitro, diversity drives innovation. We proudly celebrate the resilience and invaluable contributions of the LGBTQIA+ community during #PrideMonth and year-round. Our LGBTQIA+ employee group, outsitro, now represents over 10% of all insitrocytes, fostering an inclusive space where members feel empowered to bring their full, authentic selves to work. For many at insitro, outsitro marks their first time joining an LGBTQIA+ employee resource group. Through regular meetups, educational events, and vibrant celebrations, this growing community reinforces our commitment to cultivating an environment where all employees feel welcomed, valued, and respected. United by our diverse perspectives, we work together to achieve our mission to bring better drugs faster to the patients who can benefit most. Explore career opportunities and join us on this journey: https://lnkd.in/eTueFdYN  #insitroPride

insitro Senior Director of International Corporate Development Claire Bloomfield will speak at  HLTH Europe on a panel called, “Ghosts in the machine: Empowering healthcare to capitalize on GenAI,” on Wednesday, June 19th at 9:50 am CEST. Join Claire and industry leaders Betsabeh Madani-Hermann, Jim Swanson, and David Rhew, M.D., at #HLTHEurope in Amsterdam as they share insights on harnessing Generative AI’s potential in healthcare and for #drugdiscovery. Register for the event and learn more: https://europe.hlth.com/

We’re pleased to have our founder and CEO, Daphne Koller and our CFO/CBO, Mary Rozenman participating in the Goldman Sachs 45th Annual Global #Healthcare Conference. If you are in Miami, join us for Daphne’s fireside chat on Monday, June 10, where she will discuss the recent progress of insitro’s emerging therapeutic pipeline as we work to deliver on our mission of pipeline through platform.

On Sunday, June 2, at 3:30 p.m. ET, insitro CEO and founder Daphne Koller will join other scientists, technologists and artists for the Spring Into Science series at the #WorldScienceFestival in New York City. The panel titled “Fundamental Science in the Age of Artificial Intelligence” will feature Daphne alongside author Brian Greene, Microsoft’s Eric Horvitz and Wolfram’s Stephen Wolfram for a conversation exploring the profound role #AI is poised to play in taking human understanding to the next level. For more on the event, visit the link below.